# Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus

> **NCT03052400** · PHASE2 · TERMINATED · sponsor: **Charles Drew University of Medicine and Science** · enrollment: 8 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Insulin Resistance

## Interventions

- **DRUG:** Mifepristone 600 mg daily
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03052400
- **Lead sponsor:** Charles Drew University of Medicine and Science
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-03
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** End of Funding
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03052400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03052400, "Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT03052400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*